PROTOCOL TEMPORARY CLOSURE
GYNECOLOGIC

NRG-GY016: "A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary.”

Effective immediately, NRG-GY016 has been temporarily closed to accrual because the study has reached its maximum accrual number of 14 patients for the first stage of the trial.  Accrual will be stopped until data is matured and the analysis on the first stage is complete.

 


Memo will be available on the CTSU website within 24 hours

 

 

Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address